Related Experiment Videos
Immune hemolysis after an ABO mismatched renal transplant
A C Perkins1, V L Richards, J Gibson
1Haematology Department, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
Australian and New Zealand Journal of Medicine
|August 1, 1989
Summary
A blood group B patient experienced immune hemolysis from anti-B antibodies after a kidney transplant from a blood group O donor. This rare reaction, potentially linked to immunosuppression, required transfusions and prolonged positive direct antiglobulin tests.
Area of Science:
- Nephrology
- Immunology
- Transplantation
Background:
- Renal transplantation involves immunosuppressive therapy to prevent organ rejection.
- Blood group compatibility is crucial in transplantation to avoid hemolytic reactions.
- Cadaveric donors and recipients can have differing blood group antigens.
Observation:
- A blood group B patient developed immune hemolysis due to anti-B antibodies post-renal transplant from a blood group O donor.
- The patient required transfusional support, and the direct antiglobulin test (DAT) remained positive for 80 days.
- Cyclosporin A (CSA) was administered for rejection prophylaxis.
Findings:
- The presence of anti-B antibodies in a blood group B recipient after receiving an organ from a blood group O donor indicates a potential ABO-incompatible transplant scenario.
- Prolonged positive DAT suggests ongoing red blood cell destruction.
- The role of Cyclosporin A (CSA) in potentially facilitating this 'graft-versus-host' type reaction warrants further investigation.
Implications:
- This case highlights a rare but serious complication of ABO-incompatible kidney transplantation.
- Understanding the interplay between immunosuppression (like CSA) and alloantibody-mediated hemolysis is critical for patient management.
- Further research is needed to elucidate the mechanisms behind CSA's potential role in such hemolytic events.